Stocktoria
ARROWHEAD PHARMACEUTICALS, INC. ARWR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1993-12-14
ARROWHEAD PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $829.4M | $3.6M | $240.7M | $243.2M | $138.3M |
| R&D expense | $607.2M | $505.9M | $353.2M | — | — |
| Operating income | $98.3M | -$601.1M | -$205.0M | -$178.5M | -$149.0M |
| Interest expense | — | — | $18.3M | $0 | $0 |
| Income tax | $21.4M | -$2.8M | $2.8M | $3.8M | $2,000 |
| Net income | -$1.6M | -$599.5M | -$205.3M | -$176.1M | -$140.8M |
| EPS (diluted) | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 |
| Operating cash flow | $179.6M | -$462.9M | -$153.9M | -$136.1M | $171.3M |
| Free cash flow | $156.9M | -$604.3M | -$330.6M | -$188.9M | $147.7M |
| Cash & equivalents | — | — | — | — | $184.4M |
| Total assets | $1.4B | $1.1B | $765.6M | $691.9M | $710.1M |
| Shareholders' equity | $503.4M | $191.1M | $287.2M | $418.3M | $408.8M |
Source: SEC EDGAR filings · CIK 0000879407 · as of 2025-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.